Herbert AA, Glaab D, Schreiber R. A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis. J of Skin [Internet]. 2019Nov.9 [cited 2025Jan.9];3:S18. Available from: https://skin.dermsquared.com/skin/article/view/745